Site Search
Displaying results 51 - 60 of 64
Resource | Presentations,
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok
Resource | Presentations,
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok
Resource | Presentations,
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok
Resource | Presentations,
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok
Resource | Presentations,
By Chris Beyrer MD, MPH
Johns Hopkins Bloomberg School of Public Health
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok
Resource | Presentations,
By NittayaPhanuphak, MD, PhD
Thai Red Cross AIDS Research Centre
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok
Resource | Guidelines,
This early-release guideline makes available two key recommendations that were developed during the revision process in 2015. First, antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Second, the use of daily oral pre-exposure prophylaxis (PrEP) is recommended as a prevention choice for people at substantial risk of HIV infection as part of combination prevention approaches. The first of these recommendations is based on evidence from clinical trials and observational studies released since 2013 showing that earlier use of ART results in better clinical outcomes for people living with HIV compared with delayed treatment. The second recommendation is based on clinical trial results confirming the efficacy of the ARV drug tenofovir for use as PrEP to prevent people from acquiring HIV in a wide variety of settings and populations.
Resource | Publications,
This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing thirty key questions about PrEP and how it might be implemented in the UK.
PrEP is an HIV prevention strategy that uses antiretroviral drugs to protect HIV-negative people from HIV infection. People take antiretrovirals (ARVs) when they are at risk of exposure to HIV, in order to lower their risk of infection. Research suggests that PrEP is highly efficacious in preventing the sexual transmission of HIV, as long as the drugs are taken regularly, as directed. However, PrEP does not prevent other sexually transmitted infections or pregnancy.
Resource | Publications,
In its eleventh annual report, the HIV Vaccines and Microbicides Resource Tracking Working Group (the “Working Group”) documents biomedical HIV prevention research and development (R and D) spending for the calendar year 2014, as well as reports on an analysis of investment trends spanning fourteen years. The Working Group generates estimates of R and D investment that can be compared year to year across options and strategies and funding sources, helping assess the impact of public policies aimed at accelerating scientific progress and to provide facts for advocacy. This effort provides transparency for funders, policy makers and HIV/AIDS advocates so they can better understand and track investment flows.